You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Working with your physician » Helping a concerned physician to become comfortable with the MP
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [04.30.2019] – [Specific research] sallieqhome:starting:physician:reluctant [06.01.2019] – [Specific research] sallieq
Line 193: Line 193:
  
  
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:20074257}}))  PMID 20074257+Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{pubmed>long:20074257}}))  PMID 20074257
  
 Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450 Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450
Line 209: Line 209:
  
  
-6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:23775504}} )) PMID 23775504+6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed>long:23775504}} )) PMID 23775504 
 + 
 +Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed>long:30125396}})) PMID 30125396
  
  
Line 283: Line 285:
  
 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
 +
 +we investigated the effects of RNH-6270, an active metabolite of olmesartan, on TNF-α-induced human glomerular EC (HGEC) damage to clarify the renoprotective mechanisms of ARBs. Our findings suggested that olmesartan might have protective effects against TNF-α-induced glomerular EC dysfunction.(({{pubmed>long:    23052181}})) PMID 23052181
 +
 +We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.  (({{pubmed>long:15124927}}))  PMID 15124927
 +
 +AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in human renal proximal tubular epithelial cells (({{pubmed>long:    18331441}})) PMID 18331441
 +
 +
 +These data added to our previous results further provide a mechanistic rationale for olmesartan's antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (({{pubmed>long:26240115}})) PMID 26240115
 +
  
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.